For Healthcare Professionals

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

clipboard-pencil

About the study

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

    EXCLUSION CRITERIA

      pin location

      Study Locations

      Enter your ZIP code/Postal code/PIN code to locate study sites near you:

      How to Apply


      Contact the study center to learn if this study is a good match for you.
      Phone iconCall 1-877-240-9479Email iconEmail Study Center

      Study’s details


      Contition

      Muscle Invasive Bladder Cancer

      Age

      18+

      Phase

      Phase 3

      Participants needed

      1063

      Est. Completion Date

      Jun 2026

      Treatment type

      Interventional


      Sponsor

      AstraZeneca

      ClinicalTrials.gov identifier

      NCT03732677

      Study number

      D933RC00001

      Understanding Clinical Trials


      Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
      Vector

      Interested?

      Sign up to save your favorites, 
      receive newsletters, resources, and alerts 
      about clinical trials related to your conditions of interest.